Phibro Animal Health Corporation (NASDAQ:PAHC) Receives $28.40 Consensus Price Target from Analysts

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have earned an average rating of “Reduce” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $28.40.

Several equities analysts have commented on PAHC shares. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Bank of America upped their price target on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, August 29th. BNP Paribas Exane upgraded shares of Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price target for the company in a report on Monday, June 16th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 28th. Finally, BNP Paribas upgraded shares of Phibro Animal Health to a “hold” rating in a report on Monday, June 16th.

Phibro Animal Health Trading Up 2.0%

Phibro Animal Health stock opened at $38.81 on Wednesday. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 32.89, a PEG ratio of 1.13 and a beta of 0.89. Phibro Animal Health has a one year low of $16.16 and a one year high of $41.57. The company’s fifty day moving average price is $33.67 and its two-hundred day moving average price is $26.59.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.52 by $0.05. The firm had revenue of $378.70 million for the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd were paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Wednesday, September 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is presently 40.68%.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,022 shares of the stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $40.26, for a total value of $282,705.72. Following the completion of the sale, the chief executive officer owned 31,338 shares in the company, valued at approximately $1,261,667.88. This trade represents a 18.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 24,622 shares of company stock valued at $995,893 in the last three months. 50.07% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in Phibro Animal Health during the second quarter worth about $813,000. Ranger Investment Management L.P. increased its holdings in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares in the last quarter. State of Wyoming increased its holdings in shares of Phibro Animal Health by 148.8% during the second quarter. State of Wyoming now owns 6,608 shares of the company’s stock worth $169,000 after buying an additional 3,952 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Phibro Animal Health by 768.2% during the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after buying an additional 4,079 shares in the last quarter. Finally, State of Tennessee Department of Treasury increased its holdings in shares of Phibro Animal Health by 18.6% during the second quarter. State of Tennessee Department of Treasury now owns 26,743 shares of the company’s stock worth $683,000 after buying an additional 4,200 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.